Evidence map›Paper›PMID 40907963›Full record

ArticleJournal of the American Medical Informatics Association : JAMIA2026

Navigating the landscape of personalized oncology: overcoming challenges and expanding horizons with computational modeling.

Melike Sirlanci, David Albers, Jennifer Kwak, Clayton Smith, Tellen D Bennett, Steven M Bair

Abstract read
In one paragraph

Article in Journal of the American Medical Informatics Association : JAMIA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Melike SirlanciDepartment of Biomedical Informatics, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, United States.ORCID 0000-0002-4749-4752
David AlbersDepartment of Biomedical Informatics, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, United States.ORCID 0000-0002-5369-526X
Jennifer KwakDepartment of Radiology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, United States.
Clayton SmithDivision of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, United States.
Tellen D BennettDepartment of Biomedical Informatics, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, United States.ORCID 0000-0003-1483-4236
Steven M BairDivision of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, United States.

Funding

CANCER CLINICAL EPIDEMIOLOGY TRAINING GRANTT32CA009679 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Richard Aplenc, Karen Glanz · 1992 to 2026
$11.1M
NCI NIH HHS T32 CA009679
6 · The paper itself

Abstract

objectivesWe discuss challenges using computational modeling approaches for personalized prediction in clinical practice to predict treatment response for rare diseases treated by novel therapies using clinical oncology as an example context. Several challenges are discussed, including data scarcity, data sparsity, and difficulties in establishing interdisciplinary teams. Machine learning (ML), mechanistic modeling (MM), and hybrid modeling (HM) are discussed in the context of these challenges. MATERIALS AND

methodsWe present an HM approach, combining ML and MM techniques for improved personalized model estimation in the context of chimeric antigen receptor T-cell therapy for aggressive lymphoma.

resultsThe HM approach improved the root mean squared error by 61.27±23.21% compared to using MM alone (MM: 2.36*105∓1.68*105and HM: 9.57*104∓8.37*104, where the units are in cells), computed from 13 patients included in this study. DISCUSSION: By exploiting the complementary strengths of ML and MM approaches, the developed HM method addresses common limitations such as data scarcity and sparsity in medical settings, especially common for rare diseases.

conclusionThe HM techniques are likely required to overcome data scarcity and sparsity issues in broad medical settings. Developing these techniques requires dedicated interdisciplinary teams.

Indexed as

Computer SimulationLymphomaMachine LearningMedical OncologyPrecision MedicineHumansImmunotherapy, Adoptivecancer treatment outcome predictionhybrid modelingmachine learningmechanistic modelingpersonalized modeling

Identifiers

PMID40907963
PMCPMC12758477

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.